OUTPATIENT SUBCUTANEOUS ALEMTUZUMAB IS FEASIBLE AND SAFE FOR APLASTIC ANEMIA AND ASSOCIATED WITH HIGH RESPONSE RATES

OUTPATIENT SUBCUTANEOUS ALEMTUZUMAB IS FEASIBLE AND SAFE FOR APLASTIC ANEMIA AND ASSOCIATED WITH HIGH RESPONSE RATES

This multicenter international retrospective analysis aimed to evaluate the efficacy and safety of subcutaneous alemtuzumab (ALZ) as an alternative immunosuppressive therapy for aplastic anemia (AA). The study included 57 with AA patients who received ALZ treatment in four centers in Brazil and the...

Full description

Bibliographic Details
Main Authors: AR Fonseca, CC Justino, VC Molla, PE Yamakawa, IB Rabelo, A Hill, L Arnold, R Kelly, M Griffin, T Munir, E Velloso, T Dalessandro, AM Risitano, P Scheinberg, A Kulasekararaj, C Arrais-Rodrigues
Format: Article
Language:English
Published: Elsevier 2023-10-01
Series:Hematology, Transfusion and Cell Therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2531137923002900

Internet

http://www.sciencedirect.com/science/article/pii/S2531137923002900

Similar Items